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The importance of chronic obstructive pulmonary 
disease (COPD) as a global health problem cannot 
be overstated. According to the latest World Health 
Organization (WHO) statistics (2005), approximately 
210 million people suffer from COPD worldwide, and 
5% of all deaths globally are estimated to be caused by this disease. This 
corresponds to >3 million deaths annually, of which 90% are thought to 
occur in low- and middle-income countries. A projection published by 
the WHO Global Burden of Disease Project indicates that COPD will be 
the third leading cause of death globally by 2030.[1] Much of this burden 
will be in the developing populations of Africa, Asia and the Indian 
subcontinent. As developing countries can ill afford the added economic 
burden of COPD, there is an urgent need to understand and address the 
risk factors for the development of COPD in these countries.
While cigarette smoking remains the major risk factor, and much of 
the increase in COPD is associated with projected increases in tobacco 
use, epidemiological studies have demonstrated that in the majority of 
patients in developing countries the aetiology of COPD is multifactorial. 
Research has suggested that a quarter to almost a half of all patients with 
COPD are non-smokers.[2] Attributable fractions have been calculated 
for diverse influences such as environmental tobacco smoke exposure 
(passive smoking), smoke from biofuel combustion, exposure to dust, 
fumes and vapours, childhood illness, and previous tuberculosis (TB). 
Combinations of these risk factors are likely to be highly prevalent or 
even the rule in poor communities in developing countries, and may 
account for the greater frequency and severity of COPD in these settings. 
In this article, we summarise the epidemiology of and risk factors 
for COPD in Africa, including influences other than cigarette 
smoking that are important contributors to chronic irreversible 
airflow limitation in our setting.
Tobacco smoking 
Cigarette smoking remains the most well-documented and important 
cause of COPD. However, the old adage that ‘only 15% of smokers 
will get COPD’, and by implication the remaining 85% are immune 
to the effects of cigarette smoke, should be viewed with increasing 
scepticism. Susceptibility to the effects of smoke should rather be 
viewed as a continuous variable, not as an either/or phenomenon. 
Therefore, almost all smokers will develop reduced lung function 
if they smoke sufficient cigarettes over a sufficient period of time.[3] 
While some smokers develop very severe COPD, and the rare smoker 
is unaffected, the majority of smokers lie between these two extremes. 
Possibly a more reliable figure, derived from a large Copenhagen 
cohort, is that after 25 years of smoking, 30 - 40% of smokers with 
normal baseline lung function will develop COPD, with 25% deemed 
to have clinically significant disease.[4] 
Rather unsurprisingly, the chance of developing COPD increases 
with the number of cigarettes smoked. The adjusted hazard ratio has 
been reported to be 1.9 for smokers with a <10 pack-year history of 
smoking, and 8.8 for those with a >50 pack-year history of smoking.[5] 
Consistent with this dose-response relationship, early cessation of smoking 
has been shown to dramatically reduce the chance of developing 
severe disease.[4] However, the absence of clinical disease should not 
be viewed as reassuring, as emphysema on computed tomography 
(CT) imaging can be seen in 40% of smokers, with no evidence of 
abnormalities of lung function testing.[6]
Passive smoking, which frequently begins in early childhood, has 
also been confirmed as a risk factor for COPD. Similar to smoking, 
an exposure-response gradient exists, with greater exposure being 
associated with greater risk.[7]
Cannabis smoking and its relationship with COPD is more 
controversial and difficult to prove, as cannabis and tobacco are 
frequently smoked concurrently. Some studies suggest that heavy 
use (>20 joint-years) is associated with airflow obstruction, but these 
findings are inconsistent. In a local study, Jithoo[8] found cannabis use 
to be a strong predictor of chronic bronchitis, and concluded that the 
drug is a likely contributor to both chronic respiratory symptoms and 
possibly COPD, if not a sufficient cause in its own right.
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Airway inflammation with mucus hyper-
secretion (chronic bronchitis) as well as 
enlargement and destruction of the walls of 
the distal air spaces (emphysema) are the end 
results of cigarette smoking, and underlie 
the mechanisms of airflow obstruction 
observed in COPD. In a person with COPD, 
either chronic bronchitis or emphysema 
may predominate; however, both frequently 
coexist in varying proportions. 
Globally, the attributable fraction of cigarette 
smoking towards COPD deaths varies by both 
gender and geographical region, with cigarettes 
being responsible for more deaths from COPD in 
developed nations and in males compared with 
developing nations and females. In developed 
nations, the attributable fraction is 77 - 84% 
for men and 61 - 62% for women, while the 
corresponding rates in developing nations are 
45 - 49% and 12 - 20%, respectively.[7] In South 
Africa (SA), Groenewald et al.[9] estimated the 
overall population-attributable fraction of COPD 
to smoking as 62% overall (69% for men and 51% 
for women). However, the prevalence of smoking 
is not uniform across the entire population, with 
coloureds having the highest rates of smoking, 
followed by whites and blacks.[10]
From the abovementioned figures it is clear 
that cigarette smoking is not the only cause 
of COPD. Salvi and Barnes[2] estimate that 
25 - 45% of patients with COPD have never 
smoked. Ninety per cent of COPD deaths 
occur in low- and middle-income countries, 
and it is likely that non-smoking causes 
contribute to this excess burden of disease.[1] 
Biomass smoke exposure
Foremost among non-smoking causes of 
COPD is the use of biomass fuels for daily 
indoor cooking and heating. It is estimated 
that approximately 3 billion people worldwide 
are exposed to smoke from the burning of 
wood, dung, crop residue and other organic 
fuels. This represents 50% of all households 
and 90% of rural households, and it has been 
suggested that biomass exposure may be a 
more important global cause of COPD than 
cigarette smoking.[2] The use of stoves and 
open fires indoors, with poor ventilation, 
produces high levels of pollutants, similar 
to tobacco smoke, and places primarily 
women and young children at risk. The 
WHO estimates that biomass exposure kills 
2 million women and children, and that lung 
growth in young children may be particularly 
affected.[1] The odds ratio for the development 
of COPD in women exposed to biomass 
has been estimated at 2.40 (95% confidence 
interval (CI) 1.47 - 3.93).[11]
In 2007, 20% of SA households were said 
to be exposed to indoor smoke, with marked 
variations between the different population 
groups. Biomass use in SA was estimated 
to account for 13.1% of COPD in men and 
31.1% in women, and to be responsible for 
2 957 and 8 920 disability-adjusted life-years 
(DALYs) in men and women, respectively.[12]
Tuberculosis
The association between TB and the later 
development of COPD was previously contro-
versial; however, several large population 
cross-sectional studies have confirmed the 
association, with some studies claiming that 
it is stronger than that for either smoking or 
biomass exposure.[13-16] In an SA study, Jithoo[8] 
found that the odds ratio of TB for mild and 
moderate COPD was 2.6 (95% CI 1.5 - 4.6), 
while for severe and very severe disease is was 
8.9 (95% CI 4.2 - 18.9). Furthermore, it was 
found that almost 50% of adults >40 years of 
age with a history of previous TB had evidence 
of chronic airflow limitation.[8]
The mechanism of airflow obstruction, 
in what is increasingly being termed 
TB-associated obstructive pulmonary disease, 
remains uncertain; also whether this should 
be considered the same as smoking-related 
COPD or as a different phenotype with its own 
treatment, rate of decline and outcomes. We 
have found subtle but important physiological 
differences in these two conditions, implying 
a somewhat different pathogenesis of 
airflow limitation not accounted for by the 
presence of bronchiectasis. It is clear that 
a significant proportion of patients who 
complete TB treatment have residual chronic 
airflow limitation, with varying degrees of 
disability. Considering the estimated 9 million 
annual cases of TB globally (330 000 in SA), the 
potential problem of chronic airflow limitation 
is immense and requires urgent further study.[17] 
HIV 
The lung is a major target organ for HIV, render-
ing it susceptible to a wide array of infectious 
and non-infectious complications.[18,19] With the 
advent of early antiretroviral therapy (ART) 
and widespread antimicrobial prophylaxis, 
HIV-associated mortality[20,21] and incidence 
of opportunistic and recurrent infections[22] 
have been greatly reduced. In the developed 
world, this has resulted in a large-scale shift 
in the epidemiology of adult HIV-related 
pulmonary diseases. With a decrease in 
opportunistic infections and an increase 
in life expectancy, COPD has emerged 
as a potentially important non-infectious 
complication of HIV.[23] Preliminary cross-
sectional studies have documented a high 
prevalence of COPD among HIV-infected 
individuals, and described an association 
with risk factors such as cigarette smoking, 
previous opportunistic infections, markers 
of HIV infection and ART use.[24-30] A few 
longitudinal studies have suggested that 
the magnitude of lung function decline in 
individuals with uncontrolled HIV infection 
exceeds that which is generally attributed to 
current smoking alone.[31] Despite the high 
burden of HIV infection in sub-Saharan 
Africa, there is a paucity of data on lung 
function in HIV-infected individuals from 
this region: a study from Nigeria found 
significantly lower forced expiratory volume 
in 1 second (FEV1) values and a higher inci-
dence of COPD among HIV-positive compared 
with HIV-negative individuals,[30] while an SA 
report of a relatively young, predominantly 
female and largely non-smoking cohort of 
treated HIV-infected individuals on ART 
found that irreversible airflow obstruction 
was present in 7%,[24] a higher figure than 
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Fig. 1. Factors underlying the interaction between HIV and chronic lung disease.
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would be expected in an HIV-uninfected population with similar 
demographics.
The mechanisms behind HIV-associated COPD are unknown, 
but may result from the HIV infection, the effect of long-term ART 
and immune reconstitution, the development of autoimmunity, or 
the effects of repeated pulmonary infections, or may simply be due 
to living with HIV for an extended period of time (Fig. 1). These 
interactions have major public health implications – the direct 
and indirect effects of HIV infection, together with the projected 
increases in tobacco use, biomass fuel exposure, and high rates of 
childhood infections, have the potential to create a ‘perfect storm’ of 
chronic pulmonary disability in Africa.[32]
Occupational exposures
There is accumulating evidence that COPD is caused by occupational 
exposures to respirable dusts, smoke, vapours and fumes. The American 
Thoracic Society’s consensus statement suggests that between 10% and 
20% of COPD is attributable to workplace exposures.[33] 
In SA, much epidemiological work has been done on the association 
between respirable silica dust and airflow obstruction (independent 
of radiological silicosis) in underground gold miners.[34] In one study, 
the contribution of FEV1 loss due to silica was estimated at about 
half that of smoking 30 cigarettes a day for 30 years.[35] Although this 
effect is observed even in non-smokers, smoking and silica exposure 
are multiplicative, potentiating the development of and mortality 
from COPD.[36] Lastly, workers exposed to silica dust are at increased 
risk of developing TB, even in the absence of silicosis.[33] As described 
above, residual damage from treated TB is also associated with 
airflow obstruction and chronic respiratory symptoms. 
The association between occupational exposures to dust and 
chemicals and COPD has been demonstrated in studies of workers 
employed in other industries in Africa.[37-41] These occupational 
exposures include (but are not limited to) inorganic dust, cadmium, 
coal, organic dust, cotton, grain, diesel fumes, and welding. In a 
hospital-based case control study from KwaZulu-Natal, self-reported 
occupational exposures to biological dust or gas and fumes were 
associated with a two-fold increased odds of developing COPD, after 
adjustment for smoking and previous TB.[42]
Intra-uterine environment,  pre-
maturity and childhood respiratory 
infections
COPD may originate in childhood, or even in utero. Low-birth-
weight babies or those whose mothers smoked during pregnancy 
have reduced lung function.[43,44] Other antenatal effects that 
may negatively affect fetal lung development include maternal 
hypertension or pre-eclampsia, diabetes, medication use[45] and 
exposure to air pollution.[46] 
The effects of perinatal events, such as premature birth on lung 
function, are well documented.[47] Preterm infants have an increased 
risk of impaired lung function in infancy, childhood and adulthood, 
and an increased risk of respiratory illness. Long-term lung injury 
is caused by arrest of structural lung development at an immature 
stage (bronchopulmonary dysplasia), and is exacerbated by the use of 
mechanical ventilation and high-concentration supplemental oxygen 
in infancy.[48,49]
Severe pulmonary viral and bacterial infections in childhood 
have been shown to be associated with reduced lung function 
and obstructive spirometry in adult life.[50] Childhood infection 
damages a vulnerable lung undergoing rapid postnatal growth, and 
may also make it increasingly susceptible to additional noxious 
agents such as cigarette smoke or indoor air pollution. Postinfective 
bronchiolitis obliterans and bronchiectasis are common sequelae that 
cause chronic airflow limitation in survivors of severe childhood 
respiratory infection.
Conclusion
In the developing world, the pathogenesis of COPD is likely to 
be multifactorial. Colliding epidemics of TB, cigarette smoking, 
pulmonary infection and HIV threaten to greatly increase the burden 
of chronic lung disease in these regions.[32] There is therefore an 
urgent need to study the influences and interaction between these 
putative causative factors, particularly in Africa. 
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